[en] A double-blind, placebo-controlled, randomized, prospective two-center study was carried out to assess the effects of tibolone + fluoride versus placebo + fluoride therapy on trabecular and cortical bone in postmenopausal osteoporotic women. Ninety-four subjects (mean age 61.1 years, postmenopausal 13.5 years on average) with low bone mineral density (BMD) at baseline were randomized to 2.5 mg of tibolone (Org OD 14, Livial) plus 26.4 mg of fluoride (Fluocalcic) or placebo plus 26.4 mg of fluoride daily over 2 years; 55 (58.5%) subjects completed the study, the main reason for discontinuation being untoward gastrointestinal effects. BMD at the lumbar spine was measured by both dual photon absorptiometry (DPA) and dual-energy X-ray absorptiometry (DXA), and at the hip by DXA at 6-month intervals. Baseline values (DXA, g/cm2) for tibolone + fluoride and placebo + fluoride groups were 0.733 and 0.744 for the lumbar spine, and 0.761 and 0.788 for the hip. Change from baseline and percentage change from baseline were calculated for the intent-to-treat and completers groups. An analysis of variance (ANOVA) model or Wilcoxon test was used for statistical evaluation. There was a mean increase in BMD at the lumbar spine measured by DPA of 25.3% and 12.3% in tibolone + fluoride and placebo + fluoride groups, respectively (p = 0.01); with DXA, respective changes were 32.6% and 14.0% (p = 0.013). Data on BMD at the hip showed mean increases of 7.9% and 2.6% for the tibolone + fluoride and placebo + fluoride groups, respectively. We conclude that combined tibolone + fluoride treatment induces a highly significant increase in BMD at the lumbar spine without simultaneous loss of the cortical bone allowing for a meaningful reduction of the fluoride dose when given in combination with tibolone.
Disciplines :
Rheumatology
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Agnusdei, D.
Gennari, C.
Kicovic, P. M.
Language :
English
Title :
Association of Tibolone and Fluoride Displays a Pronounced Effect on Bone Mineral Density in Postmenopausal Osteoporotic Women
Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50
Albright F, Smith PH, Richardson AM. Post-menopausal osteoporosis. J Am Med Assoc 1941;116:2465-74
Devogelaer JP, Boutsen Y, Nagant de Deuxchaisnes C. A randomized controlled trial of ADP given intravenously with and without sodium fluoride in involutional osteoporosis. In Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen: Osteopress, 1990:1504-6
Reginster J-Y, Caulin F, Huyghe C, et al. Bone effect of intermittent cyclical calcitonin and intermittent cyclical fluoride and calcitonin in the treatment of postmenopausal osteoporosis. In Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen: Osteopress, 1990:1495-6
Gambacciani M, Spinetti A, Cappagli A, et al. Effects of low-dose monofluorophosphate and transdermal oestradiol in postmenopausal vertebral bone loss. Eur Men J 1995;2(2):16-20
Kicovic PM, Cortes-Prieto J, Luisi M, et al. Placebo-controlled cross-over study of effects of Org OD14 in postmenopausal women. Reproduction 1982;6:81-91
Benedck-Jaszmann LJ. Long-term placebo-controlled efficacy and safety study of Org OD14 in climacteric women. Maturitas 1987;Suppl 1:25-33
Lindsay R, Hart DM, Kraszewsky A. Prospective double-blind trial of synthetic steroid (Org OD14) for preventing postmenopausal osteoporosis. Br Med J 1980;280:1207-9
Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994;4:314-9
Bjarnason N, Bjarnason K, Haarbo J, et al. Tibolone: prevention of bone loss in late post-menopausal women. J Clin Endocrinol Metab 1996;81:2419-22
Berning B, v. Kuijk C, Kuiper JW, et al. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two year randomized placebo controlled study. Bone 1996;19(4):395-9
Geusens P, Dequeker J, Gielen J, et al. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas 1991;13:155-62
Studd J, Arnala I, Kicovic PM, et al. A randomised study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998;92(4):574-9
Punnonen R, Liukko P, Cortel-Prieto J, et al. Multicentre study of effects of Org OD14 on endometrium, vaginal cytology and cervical mucus in postmenopausal and oophorectomized women. Maturitas 1984;5:281-6
Genazzani AR, Benedek-Jaszmann LJ, Hart DM, et al. Org OD14 and the endometrium. Maturitas 1991;13:243-51
Reginster J-Y, Denis D, Deroisy R, et al. Dual photon absorptiometry of lumbar spine in west European (Belgian) postmenopausal females: normal range and fracture threshold. Clin Rheumatol 1990;9(2):220-4
Reginster J-Y, Janssen C, Deroisy R, et al. Bone mineral density of the spine and the hip measured with dual energy x-ray absorptiometry: normal range and fracture treshold for Western European (Belgian) postmenopausal females. Cain Rheumatol 1995;14(1):68-75
Mamelle N, Meunier PJ, Dusan R et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988;2:361-5
Riggs BL, Hodgson SF, O'Fallon WM et al. Effect of fluoride treatment on the fracture rate in post-menopausal women with osteoporosis. N Engl J Med 1990;322:802-9
Heaney RP, Baylink DJ, Johnston CC et al. Fluoride therapy for the vertebral crush fracture syndrome. Ann Intern Med 1989;111:678-80
Compston JE, Yamaguchi K, Croucher PI et al. The effects of gonadotropin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 1995;16(2):261-7